Tapentadol ER Versus Oxycodone
Links shared publicly online about this topic
Tapentadol ER Demonstrates Better GI Tolerability When Compared with Oxycodone CR - ONA
oncologynurseadvisor.com — “Results of a post-hoc analysis presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that tapentadol extended-release is associated with comparable analgesia and better gastrointestinal tolerability than oxycodone HCl controlled-release.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 20, 2011 at 5:57 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Tapentadol ER Demonstrates Better GI Tolerability When Compared with Oxycodone CR http://goo.gl/fb/zmaRJ
Tapentadol ER Demonstrates Better GI Tolerability When Compared with Oxycodone CR - MPR
empr.com — “Results of a post-hoc analysis presented at the American Pain Society’s 30th Annual Scientific Meeting demonstrated that tapentadol extended-release is associated with comparable analgesia and better gastrointestinal tolerability than oxycodone HCl controlled-release.” View full resource at empr.com
Most Recently Shared on May 20, 2011 at 6:20 pm By:
MPR News: Tapentadol ER Demonstrates Better GI Tolerability When Compared with Oxycodone CR: Results of a post-h... http://bit.ly/mgzB9z
Tapentadol Extended Release Associated with Lower Rates, Longer Times to Discontinuation Due to Gastrointestinal Adverse Events than Oxycodone Controlled-Release - MPR
empr.com — “Prior opioid experience had no effect on discontinuation of tapentadol extended-release (ER) due to gastrointestinal treatment-emergent adverse events (TEAEs) in patients with moderate-to-severe chronic low back or osteoarthritis pain, investigators reported during the American Pain Society's 29th Annual Scientific Meeting.” View full resource at empr.com
Most Recently Shared on May 6, 2010 at 9:34 pm By:
APS: Tapentadol Extended Release Associated with Lower Rates, Longer Times to Discontinuation Due to Gastrointesti... http://bit.ly/a08qSw
Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended-Release vs Oxycodone Controlled-Release Due to Adverse Events - ONA
oncologynurseadvisor.com — “Tapentadol extended-release (ER), an investigational drug, was associated with better gastrointestinal tolerability in elderly patients with moderate-to-severe chronic pain, with fewer discontinuing the study due to treatment-emergent adverse events (TEAEs) than oxycodone controlled-release (CR), investigators concluded in a presentation during the 29th Annual Scientific Meeting of the American Pain Society.” View full resource at oncologynurseadvisor.com
Most Recently Shared on May 8, 2010 at 1:48 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended… http://goo.gl/fb/DK60M
Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended-Release vs Oxycodone Controlled-Release Due to Adverse Events - MPR
empr.com — “Tapentadol extended-release (ER), an investigational drug, was associated with better gastrointestinal tolerability in elderly patients with moderate-to-severe chronic pain, with fewer discontinuing the study due to treatment-emergent adverse events (TEAEs) than oxycodone controlled-release (CR), investigators concluded in a presentation during the 29th Annual Scientific Meeting of the American Pain Society.” View full resource at empr.com
Most Recently Shared on May 8, 2010 at 2:42 pm By:
APS: Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended-Release vs Oxycod... http://bit.ly/9yMFpG
Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients With Chronic Low Back Pain - Drugs.com MedNews
drugs.com — “Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to” View full resource at drugs.com
Most Recently Shared on September 27, 2010 at 2:10 pm By:
Drugs and Devices OW OW Health
Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients With Chronic Low Back Pain:... http://bit.ly/cqnARq #drug
Phase 3 Study Compares Tapentadol Extended Release Tablets To Placebo In Patients With Chronic Low Back Pain - QualityPoint Technologies
qualitypointtech.net — “Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic low back pain have been published online by Expert Opinion on Pharmacotherapy. In addition, this study compared oxycodone controlled-release (CR) to placebo as an active control. Tapentadol ER vs. Placebo The study demonstrated that a significantly higher percentage of patients receiving tapentadol ER tablets achieved at l” View full resource at qualitypointtech.net
Most Recently Shared on September 28, 2010 at 12:00 pm By:
Phase 3 Study Compares Tapentadol Extended Release Tablets To Placebo In Patients With Chronic Low Back Pain: Phas... http://bit.ly/cPcs1D
Emergency Med Medical News about Bupivacaine Oxycodone Peripheral Vascular Diseases Injections, Epidural
mdlinx.com — “Pain Management in Peripheral Arterial Obstructive Disease: Oral Slow-Release Oxycodone Versus Epidural l-Bupivacaine” View full resource at mdlinx.com
Most Recently Shared on March 26, 2010 at 2:16 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Pain Management in Peripheral Arterial Obstructive Disease: Oral Slow-Release Oxycodone Versus Epidural... http://bit.ly/dwyWOD #ER #mdlinx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
